The magic of the holidays was in full effect this month at Watercrest Spanish Springs Assisted Living and Memory Care.

Opdivo Qvantig is the first subcutaneously administered PD-1 inhibitor approved by the FDA. It is expected to be available in ...

The US Food and Drug Administration (FDA) on Friday approved nivolumab and hyaluronidase-nvhy, under the trade name Opdivo ...

Opdivo Qvantig offers a faster delivery for patients to receive this immunotherapy treatment option in three to five minutes ...

Bristol Myers Squibb (BMY) announced Friday that the U.S. Food and Drug Administration has approved Opdivo Qvantig (nivolumab and ...

Shares of Bristol Myers Squibb ($BMY) were in the spotlight on Friday after the U.S. Food and Drug Administration approved an ...

Trump administration adviser Elon Musk angered MAGA supporters with his approval of a social media post sarcastically explaining that immigrants are needed for tech jobs because U.S. workers aren’t qu ...

Citius Oncology, Inc. ("Citius Oncology" or the "Company") , a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies, today reported ...

In January 2024, the FDA approved erdafitinib (Balversa) for adult patients with locally advanced or metastatic urothelial ...

Opdivo Qvantig is approved for solid tumors, including melanoma, renal cell carcinoma, and non-small cell lung cancer. The ...

On December 27, 2024, subcutaneous nivolumab (Opdivo Qvantig) was approved by the FDA in all previously approved adult solid ...

The Food and Drug Administration announced it has approved nivolumab and hyaluronidase-nvhy, Opdivo Qvantig, from Bristol Myers (BMY) Squibb, ...